Does the media favor ELMD or INSP?

In the previous week, Electromed and Electromed both had 1 articles in the media. Electromed's average media sentiment score of 1.91 beat Inspire Medical Systems' score of 0.00 indicating that Electromed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Electromed 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Inspire Medical Systems 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, CDRE or ELMD?

Cadre has higher revenue and earnings than Electromed. Cadre is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cadre $610.31M 1.97 $44.14M $0.89 31.55 Electromed $71.75M 4.46 $5.15M $1.17 33.06

Is CDRE or ELMD more profitable?

Electromed has a net margin of 11.34% compared to Cadre's net margin of 5.80%. Electromed's return on equity of 15.71% beat Cadre's return on equity. Company Net Margins Return on Equity Return on Assets Cadre 5.80% 12.39% 5.08% Electromed 11.34% 15.71% 13.37%

Does the media refer more to CDRE or ELMD?

In the previous week, Cadre had 3 more articles in the media than Electromed. MarketBeat recorded 4 mentions for Cadre and 1 mentions for Electromed. Electromed's average media sentiment score of 1.91 beat Cadre's score of -0.06 indicating that Electromed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cadre 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Electromed 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation & earnings, IRMD or ELMD?

iRadimed has higher revenue and earnings than Electromed. Electromed is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iRadimed $83.81M 14.06 $22.48M $1.83 50.38 Electromed $71.75M 4.46 $5.15M $1.17 33.06

Is IRMD or ELMD more profitable?

iRadimed has a net margin of 27.36% compared to Electromed's net margin of 11.34%. iRadimed's return on equity of 24.48% beat Electromed's return on equity. Company Net Margins Return on Equity Return on Assets iRadimed 27.36% 24.48% 21.25% Electromed 11.34% 15.71% 13.37%

Do analysts recommend AVNS or ELMD?

Electromed has a consensus target price of $37.50, indicating a potential downside of 3.05%. Given Electromed's stronger consensus rating and higher possible upside, analysts plainly believe Electromed is more favorable than Avanos Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avanos Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Electromed 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25

Electromed (ELMD) Competitors

$38.68 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$38.72 +0.04 (+0.10%)

As of 06/18/2026 05:55 PM Eastern

Compare

ELMD vs. INSP, CDRE, IRMD, AVNS, and TNDM

Should you buy Electromed stock or one of its competitors? MarketBeat compares Electromed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Electromed include Inspire Medical Systems (INSP), Cadre (CDRE), iRadimed (IRMD), Avanos Medical (AVNS), and Tandem Diabetes Care (TNDM). These companies are all part of the "medical equipment" industry.

How does Electromed compare to Inspire Medical Systems?

Electromed (NYSE:ELMD) and Inspire Medical Systems (NYSE:INSP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

Electromed presently has a consensus target price of $37.50, suggesting a potential downside of 3.05%. Inspire Medical Systems has a consensus target price of $81.84, suggesting a potential upside of 91.83%. Given Inspire Medical Systems' higher possible upside, analysts plainly believe Inspire Medical Systems is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25
Inspire Medical Systems	3 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10

Inspire Medical Systems has a net margin of 14.33% compared to Electromed's net margin of 11.34%. Electromed's return on equity of 15.71% beat Inspire Medical Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
Inspire Medical Systems	14.33%	10.35%	8.81%

Inspire Medical Systems has higher revenue and earnings than Electromed. Inspire Medical Systems is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$71.75M	4.46	$5.15M	$1.17	33.06
Inspire Medical Systems	$911.98M	1.35	$145.42M	$4.49	9.50

Electromed has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. Comparatively, Inspire Medical Systems has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market.

In the previous week, Electromed and Electromed both had 1 articles in the media. Electromed's average media sentiment score of 1.91 beat Inspire Medical Systems' score of 0.00 indicating that Electromed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Electromed	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Inspire Medical Systems	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

40.8% of Electromed shares are owned by institutional investors. Comparatively, 94.9% of Inspire Medical Systems shares are owned by institutional investors. 10.5% of Electromed shares are owned by insiders. Comparatively, 2.2% of Inspire Medical Systems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Electromed and Inspire Medical Systems tied by winning 8 of the 16 factors compared between the two stocks.

How does Electromed compare to Cadre?

Cadre (NYSE:CDRE) and Electromed (NYSE:ELMD) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

44.0% of Cadre shares are held by institutional investors. Comparatively, 40.8% of Electromed shares are held by institutional investors. 30.1% of Cadre shares are held by insiders. Comparatively, 10.5% of Electromed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cadre has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, Electromed has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

Cadre has higher revenue and earnings than Electromed. Cadre is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadre	$610.31M	1.97	$44.14M	$0.89	31.55
Electromed	$71.75M	4.46	$5.15M	$1.17	33.06

Cadre presently has a consensus target price of $39.75, suggesting a potential upside of 41.55%. Electromed has a consensus target price of $37.50, suggesting a potential downside of 3.05%. Given Cadre's higher possible upside, equities research analysts clearly believe Cadre is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadre	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Electromed	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Electromed has a net margin of 11.34% compared to Cadre's net margin of 5.80%. Electromed's return on equity of 15.71% beat Cadre's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadre	5.80%	12.39%	5.08%
Electromed	11.34%	15.71%	13.37%

In the previous week, Cadre had 3 more articles in the media than Electromed. MarketBeat recorded 4 mentions for Cadre and 1 mentions for Electromed. Electromed's average media sentiment score of 1.91 beat Cadre's score of -0.06 indicating that Electromed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cadre	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Electromed	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Electromed beats Cadre on 8 of the 15 factors compared between the two stocks.

How does Electromed compare to iRadimed?

iRadimed (NASDAQ:IRMD) and Electromed (NYSE:ELMD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

In the previous week, Electromed had 1 more articles in the media than iRadimed. MarketBeat recorded 1 mentions for Electromed and 0 mentions for iRadimed. Electromed's average media sentiment score of 1.91 beat iRadimed's score of 0.00 indicating that Electromed is being referred to more favorably in the news media.

Company	Overall Sentiment
iRadimed	Neutral
Electromed	Very Positive

iRadimed has higher revenue and earnings than Electromed. Electromed is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81M	14.06	$22.48M	$1.83	50.38
Electromed	$71.75M	4.46	$5.15M	$1.17	33.06

iRadimed has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Electromed has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

92.3% of iRadimed shares are owned by institutional investors. Comparatively, 40.8% of Electromed shares are owned by institutional investors. 34.6% of iRadimed shares are owned by company insiders. Comparatively, 10.5% of Electromed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

iRadimed has a net margin of 27.36% compared to Electromed's net margin of 11.34%. iRadimed's return on equity of 24.48% beat Electromed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	27.36%	24.48%	21.25%
Electromed	11.34%	15.71%	13.37%

iRadimed presently has a consensus price target of $120.00, indicating a potential upside of 30.15%. Electromed has a consensus price target of $37.50, indicating a potential downside of 3.05%. Given iRadimed's higher probable upside, research analysts clearly believe iRadimed is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Electromed	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Summary

iRadimed beats Electromed on 11 of the 15 factors compared between the two stocks.

How does Electromed compare to Avanos Medical?

Avanos Medical (NYSE:AVNS) and Electromed (NYSE:ELMD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

95.2% of Avanos Medical shares are owned by institutional investors. Comparatively, 40.8% of Electromed shares are owned by institutional investors. 2.3% of Avanos Medical shares are owned by insiders. Comparatively, 10.5% of Electromed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Electromed had 1 more articles in the media than Avanos Medical. MarketBeat recorded 1 mentions for Electromed and 0 mentions for Avanos Medical. Electromed's average media sentiment score of 1.91 beat Avanos Medical's score of 0.00 indicating that Electromed is being referred to more favorably in the news media.

Company	Overall Sentiment
Avanos Medical	Neutral
Electromed	Very Positive

Avanos Medical has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market. Comparatively, Electromed has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

Electromed has a consensus target price of $37.50, indicating a potential downside of 3.05%. Given Electromed's stronger consensus rating and higher possible upside, analysts plainly believe Electromed is more favorable than Avanos Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avanos Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Electromed	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Electromed has lower revenue, but higher earnings than Avanos Medical. Avanos Medical is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avanos Medical	$701.20M	1.67	-$72.90M	-$1.61	N/A
Electromed	$71.75M	4.46	$5.15M	$1.17	33.06

Electromed has a net margin of 11.34% compared to Avanos Medical's net margin of -10.39%. Electromed's return on equity of 15.71% beat Avanos Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avanos Medical	-10.39%	5.39%	3.97%
Electromed	11.34%	15.71%	13.37%

Summary

Electromed beats Avanos Medical on 14 of the 17 factors compared between the two stocks.

How does Electromed compare to Tandem Diabetes Care?

Tandem Diabetes Care (NASDAQ:TNDM) and Electromed (NYSE:ELMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Electromed has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.01B	1.03	-$204.71M	-$1.40	N/A
Electromed	$71.75M	4.46	$5.15M	$1.17	33.06

40.8% of Electromed shares are owned by institutional investors. 2.1% of Tandem Diabetes Care shares are owned by company insiders. Comparatively, 10.5% of Electromed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Tandem Diabetes Care has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market. Comparatively, Electromed has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

Electromed has a net margin of 11.34% compared to Tandem Diabetes Care's net margin of -9.20%. Electromed's return on equity of 15.71% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%
Electromed	11.34%	15.71%	13.37%

Tandem Diabetes Care presently has a consensus price target of $29.84, indicating a potential upside of 95.05%. Electromed has a consensus price target of $37.50, indicating a potential downside of 3.05%. Given Tandem Diabetes Care's higher possible upside, analysts plainly believe Tandem Diabetes Care is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.48
Electromed	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

In the previous week, Electromed had 1 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 1 mentions for Electromed and 0 mentions for Tandem Diabetes Care. Electromed's average media sentiment score of 1.91 beat Tandem Diabetes Care's score of -2.00 indicating that Electromed is being referred to more favorably in the news media.

Company	Overall Sentiment
Tandem Diabetes Care	Very Negative
Electromed	Very Positive

Summary

Electromed beats Tandem Diabetes Care on 12 of the 16 factors compared between the two stocks.

Get Electromed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELMD vs. The Competition

Export

Metric	Electromed	Electromedical equipment Industry	Medical Sector	NYSE Exchange
Market Cap	$320.27M	$72.35M	$6.42B	$23.21B
Dividend Yield	N/A	N/A	2.68%	4.06%
P/E Ratio	51.57	8.60	24.73	31.61
Price / Sales	4.46	191.71	528.42	22.84
Price / Cash	41.36	41.36	45.07	24.44
Price / Book	7.58	4.91	10.83	4.68
Net Income	$5.15M	-$5.50M	$3.57B	$1.08B
7 Day Performance	4.15%	-3.24%	0.71%	-0.82%
1 Month Performance	0.81%	-13.57%	3.97%	3.12%
1 Year Performance	86.50%	210.17%	28.54%	24.66%

Electromed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELMD Electromed	1.3445 of 5 stars	$38.68 flat	$37.50 -3.1%	+86.5%	$320.27M	$71.75M	51.57	160	Positive News
INSP Inspire Medical Systems	3.6433 of 5 stars	$41.80 +1.6%	$81.84 +95.8%	-67.2%	$1.20B	$911.98M	9.29	1,333
CDRE Cadre	4.3104 of 5 stars	$28.05 -3.6%	$39.75 +41.7%	-16.9%	$1.20B	$610.31M	31.40	2,533	Insider Trade
IRMD iRadimed	2.5207 of 5 stars	$92.62 +2.0%	$120.00 +29.6%	+57.7%	$1.18B	$83.81M	50.61	110
AVNS Avanos Medical	0.4672 of 5 stars	$24.97 +0.0%	N/A	+106.5%	$1.17B	$701.20M	N/A	2,287

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ELMD) was last updated on 6/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Electromed (ELMD) Competitors

ELMD vs. INSP, CDRE, IRMD, AVNS, and TNDM

How does Electromed compare to Inspire Medical Systems?

Summary

How does Electromed compare to Cadre?

Summary

How does Electromed compare to iRadimed?

Summary

How does Electromed compare to Avanos Medical?

Summary

How does Electromed compare to Tandem Diabetes Care?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELMD vs. The Competition

Electromed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Electromed (ELMD) Competitors

ELMD vs. INSP, CDRE, IRMD, AVNS, and TNDM

How does Electromed compare to Inspire Medical Systems?

Do analysts prefer ELMD or INSP?

Is ELMD or INSP more profitable?

Which has higher earnings & valuation, ELMD or INSP?

Which has more volatility and risk, ELMD or INSP?

Does the media favor ELMD or INSP?

Do insiders and institutionals have more ownership in ELMD or INSP?

Summary

How does Electromed compare to Cadre?

Do institutionals and insiders have more ownership in CDRE or ELMD?

Which has more risk and volatility, CDRE or ELMD?

Which has stronger earnings and valuation, CDRE or ELMD?

Do analysts prefer CDRE or ELMD?

Is CDRE or ELMD more profitable?

Does the media refer more to CDRE or ELMD?

Summary

How does Electromed compare to iRadimed?

Does the media refer more to IRMD or ELMD?

Which has better valuation & earnings, IRMD or ELMD?

Which has more risk and volatility, IRMD or ELMD?

Do insiders and institutionals believe in IRMD or ELMD?

Is IRMD or ELMD more profitable?

Do analysts rate IRMD or ELMD?

Summary

How does Electromed compare to Avanos Medical?

Do institutionals & insiders believe in AVNS or ELMD?

Does the media prefer AVNS or ELMD?

Which has more risk and volatility, AVNS or ELMD?

Do analysts recommend AVNS or ELMD?

Which has preferable earnings & valuation, AVNS or ELMD?

Is AVNS or ELMD more profitable?

Summary

How does Electromed compare to Tandem Diabetes Care?

Which has preferable valuation and earnings, TNDM or ELMD?

Do institutionals and insiders believe in TNDM or ELMD?

Which has more volatility & risk, TNDM or ELMD?

Is TNDM or ELMD more profitable?

Do analysts rate TNDM or ELMD?

Does the media refer more to TNDM or ELMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELMD vs. The Competition

Electromed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools